An experimental drug named Kylo-11 reduced a key cardiovascular risk substance by 97 percent after a single injection in a clinical trial. High concentrations of lipoprotein in the blood directly increase the chances of suffering a stroke or a heart attack.
Results from the trial, published in the medical journal The Lancet, demonstrated that a single dose starting from 225 mg maintained reduced lipoprotein levels for up to 48 weeks, or roughly 11 months. The maximum 97 percent reduction was recorded at the highest tested dose of 600 mg.
Dual action mechanism in the liver
Kylo-11 is a non-canonical, long-acting small interfering RNA inhibitor designed to halt the production of lipoprotein directly inside the liver. Lipoproteins are particles that transport lipids through the bloodstream, and elevated concentrations are strongly associated with plaque buildup, arterial narrowing, and cardiovascular disease.
The treatment operates through a dual-site conjugation mechanism by positioning itself at two distinct locations within liver cells. Standard RNA silencers bind to only a single receptor site. According to the study, this dual attachment enables Kylo-11 to build a more stable and durable intracellular reservoir in the liver, extending its protective effect over many months.
Small interfering RNA therapies work by targeting messenger RNA molecules to suppress specific disease-causing proteins before they can be produced by the body.
Trial safety and patient adherence
The Phase 1 trial evaluated the drug in 71 patients over a one-year monitoring period following a single subcutaneous dose. Researchers reported that participants experienced only mild or moderate side effects, with no severe adverse reactions or deaths related to the treatment.
Phase 1 clinical trials represent the standard first phase of human testing, designed primarily to evaluate safety, side effects, and dosing parameters. The study highlighted that longer intervals between injections could substantially improve patient adherence to treatment. Standard cardiovascular therapies often require lifelong daily or frequent administration, making extended-duration injectable medications a promising potential alternative.
Further studies required for clinical efficacy
Researchers noted that because the initial trial focused on safety and dosage, Kylo-11 must now be tested in a broader and more diverse patient population to evaluate its effects across different demographic groups.
The study authors explained that while the drug produces a drastic and long-lasting reduction of lipoprotein in the blood, future advanced phase clinical trials are still needed to confirm whether this chemical decrease actually leads to a real-world reduction in heart attacks and strokes for patients in daily life.
